Deutsche Bank raises Bayer stock price target on stronger earnings
Deutsche Bank raised its price target on Bayer AG to EUR65.00 from EUR60.00, maintaining a Buy rating. The firm increased its 2026 adjusted EBITDA forecast to EUR10,060 million, driven by stronger pharmaceutical performance. Bayer's stock has surged 109% over the past year, trading at $15.91. The company reported Q3 2026 earnings of $0.0868 per share on revenue of $11.26 billion, missing expectations but raising full-year guidance.
How this was made
The 30-second read
Why it matters
The higher target and improved forecasts could attract buying interest, especially in the pharma segment, while crop‑science headwinds remain a risk.
Market read
Analyst upgrade on a large-cap European ADR may influence short‑term price action and sector sentiment.
What to watch
Litigation cash outflows and pending glyphosate settlement could weigh on Bayer despite the upgrade.
Background
Deutsche Bank's analyst team revised Bayer's valuation after the company reported stronger third‑quarter performance and raised its 2026‑2028 EBITDA guidance.
Ticker impact
Deutsche Bank raised Bayer's price target to EUR65 from EUR60, citing stronger earnings and upgraded 2026‑2028 EBITDA forecasts.
likely upward pressure as investors price in the higher target and improved guidance
The target raise reflects better-than-expected pharma performance and higher EBITDA multiples, which typically drive buying interest.
Market effects
Pharma sector may see modest rally as Bayer's upgraded outlook lifts peer sentiment.
European markets could benefit from the positive news on a major German conglomerate.
Limited to investors tracking large-cap healthcare stocks and ADRs.
Counterpoint
The upgrade may be premature if crop division challenges persist, potentially capping upside.
Key entities
- companyBayer AG
German life‑science and agricultural chemicals group.
- financial_institutionDeutsche Bank
Investment bank providing the analyst upgrade.

